Recurrent Stage 4 Ovarian Cancer on Targeted Therapy: What a 70% Tumor Shrinkage Means, Anti-VEGF Drugs, PARP Inhibitors and ADCs, Side Effects to Watch and the Real Evidence on Mind-Body Care

A question from a cancer support group: 26 years with ovarian cancer, a third recurrence at stage 4, the 30th dose of targeted therapy and a 70% shrinkage

Short answer: a 70% shrinkage with other lesions stable means the drug is working very well, but treatment and close side-effect monitoring still need to continue because the disease is still present.

A member of a cancer support group shared that she was diagnosed with ovarian cancer at 33, stayed in remission for more than 20 years, and then had a third recurrence at stage 4 with spread in the abdomen. She is now on her 30th dose of targeted therapy; the main tumor has shrunk 70% and other lesions are stable. She draws on Buddhist practice and sees cancer as a lost cell to steady her mind.
This guide summarizes what that response means, which targeted drug classes are used in ovarian cancer, the side effects to watch and the real evidence on the mind and treatment. It has not reviewed her history or results, so it is not a diagnosis.

1. What a 70% shrinkage with stable lesions means

Short answer: under RECIST 1.1, a decrease of 30% or more in the sum of tumor diameters is a partial response, so 70% is a very good response. Stable lesions mean the drug is holding them back.

The language doctors use when reading scans

Stable disease does not mean the drug has failed. In metastatic cancer, stopping growth is a real benefit. Doctors combine CT scans, the CA-125 tumor marker, symptoms and side effects to decide whether to continue.

Why a long gap before recurrence matters

The ESMO-ESGO (2019) recommendations guide drug choice by the platinum-free interval, pathology, BRCA or homologous recombination deficiency (HRD) status and previous treatments.
A recurrence after a long interval usually still responds better to platinum than an early recurrence. Some patients alternate between remission and treatment for years, much like a chronic illness.

2. Three targeted drug classes in ovarian cancer: what a 30th dose could be

Short answer: the targeted drugs given intravenously in cycles for ovarian cancer are usually anti-angiogenic antibodies and antibody-drug conjugates. PARP inhibitors are tablets. The surest way to know is to ask your care team for the generic name.

Class 1: anti-angiogenic (anti-VEGF) antibodies such as bevacizumab

In platinum-sensitive disease, the OCEANS trial (484 patients) found that adding bevacizumab to chemotherapy and continuing it extended progression-free survival from 8.4 to 12.4 months and raised the response rate from 57.4% to 78.5%.
In platinum-resistant disease, AURELIA (361 patients) found progression-free survival rose from 3.4 to 6.7 months, but overall survival did not differ significantly (16.6 vs 13.3 months). The drug is usually given every 2–3 weeks, so doses can add up to several dozen.

Class 2: PARP inhibitors (olaparib, niraparib) are tablets

They are used as maintenance after a response to platinum and work best with a BRCA mutation or HRD. In SOLO2 (295 patients), median overall survival was 51.7 months with olaparib vs 38.8 months with placebo (a 12.9-month difference). Severe anemia occurred in 21%.

Class 3: antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine

An antibody delivers a chemotherapy payload to cancer cells with high folate receptor alpha (FRα), so tumor testing is needed first. In MIRASOL (453 patients with platinum-resistant disease), the response rate was 42.3% vs 15.9% and median overall survival 16.46 vs 12.75 months compared with investigator-chosen chemotherapy. It is given intravenously every 3 weeks.

Is repeat surgery an option?

In DESKTOP III (407 patients), selected patients likely to have all visible tumor removed had a median overall survival of 53.7 months vs 46.0 months with chemotherapy alone; those with complete resection reached a median of 61.9 months. It is not suitable for everyone, especially with widespread abdominal disease.

Targeted drugs in recurrent ovarian cancer, generic names and drug classes only (shown as cards on mobile)

3. Targeted therapy is not side-effect free: what to monitor every cycle

Short answer: targeted drugs have different side effects from chemotherapy, not none at all. Reaching 30 doses safely comes from monitoring every cycle.

Blood pressure and urine protein

In OCEANS, severe high blood pressure occurred in 17.4% and severe proteinuria in 8.5% of patients on bevacizumab. Most cases are controlled with blood pressure medicine, which is why urine and blood pressure are checked before each dose. Very high values may lead to a delay or pause.

Bowel perforation risk with peritoneal spread

AURELIA reported bowel perforation in 2.2% and excluded patients with a history of bowel obstruction from the start. People whose cancer coats the bowel or peritoneum need to recognize obstruction and perforation symptoms and go to hospital at once if any red flag appears.

Surgery wounds and dental work

Anti-angiogenic drugs slow wound healing, so treatment usually pauses for several weeks before and after major surgery as the doctor directs. Tell every dentist and doctor that you are on this drug.

4. A mind bigger than the disease: the real evidence on mind and cancer

Short answer: mindfulness and emotional care genuinely reduce suffering and improve quality of life, but no randomized trial has confirmed they shrink tumors or extend survival. The mind is a companion to medicine, not a replacement.

What mindfulness can help with

A meta-analysis of 29 randomized trials with 3,274 participants
(Cillessen 2019)
found mindfulness programs reduced psychological distress (effect size g = 0.32 after the program and 0.19 at follow-up) and helped with anxiety, depression, fear of recurrence, fatigue, sleep and pain (g 0.20–0.51). Most effects were small, but they matter for people living with long-term treatment.

Stress and immunity: what we know and what we do not

A study of 42 women with ovarian cancer (Lutgendorf 2005) found that higher social support was associated with greater natural killer (NK) cell activity and higher distress with lower activity. This is an association; it does not prove that a calm mind shrinks tumors.
A review in Psychological Bulletin (2007) concluded that no well-designed randomized trial has shown that psychotherapy extends survival in cancer.

Seeing cancer as a lost cell: a valid tool for coping

Meeting cancer with compassion rather than hatred is a coping approach that can ease fear and anger, and it fits the science: cancer is our own cell whose growth controls have gone wrong. The key is to use it alongside medical treatment, and not to blame yourself on days when your mind is not calm, because treatment results do not depend on mental strength.

Moving the body

The American College of Sports Medicine (2019) guidelines recommend about 30 minutes of moderate aerobic activity 3 times a week plus resistance training twice a week to reduce anxiety, depression and fatigue and improve quality of life, adjusted to energy on treatment days.

Evidence for mind and body care (shown as cards on mobile)

5. Comparing treatment and care options in recurrent ovarian cancer

Short answer: medical treatment is the core of disease control. Repeat surgery suits selected patients, while mind and body care helps people tolerate treatment longer and live better.

Options compared, generic names and drug classes only (shown as cards on mobile)

Do and don’t during long-term targeted therapy

Practical rules with reasons (shown as cards on mobile)

Frequently asked questions (FAQ)

Common questions from people with ovarian cancer and caregivers about recurrence and targeted therapy

My main ovarian tumor shrank 70% while other lesions are stable. What does that mean?

Under the RECIST 1.1 criteria doctors use to measure response, a decrease of 30% or more in the sum of measurable tumor diameters counts as a partial response, so a 70% shrinkage is a very good response. Stable lesions mean the drug is stopping them from growing, which also counts as benefit, but it is not the same as the disease being gone. Treatment usually continues with regular scans and CA-125 checks.

What could a 30th dose of targeted therapy for ovarian cancer be?

The intravenous targeted drugs commonly given in cycles for ovarian cancer are the anti-angiogenic antibody bevacizumab, usually every 3 weeks, and antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine for tumors with high folate receptor alpha. PARP inhibitors such as olaparib and niraparib are daily tablets, not injections. The surest way to know is to ask your doctor or pharmacist for the generic name.

Is it true that targeted therapy has no side effects?

No. Targeted drugs simply have different side effects from chemotherapy. Anti-angiogenic drugs can cause high blood pressure, protein in the urine, poor wound healing, bleeding and bowel perforation; the AURELIA trial reported bowel perforation in 2.2% of patients. PARP inhibitors cause anemia, low platelets, nausea and fatigue. ADCs can affect the eyes, such as blurred vision, and the nerves. Blood tests, blood pressure and urine checks are done before each cycle.

How can ovarian cancer come back after 20 years in remission?

It is uncommon but possible. A small number of cancer cells can stay dormant and undetectable for years before dividing again. A recurrence after a long interval usually responds better to platinum drugs than an early recurrence. Doctors look at the platinum-free interval, the pathology and genetic testing such as BRCA to choose the right drugs for each person.

Can a calm mind, mindfulness or forgiveness make a cancer tumor shrink?

Current evidence does not confirm that a calm mind shrinks tumors or extends survival. A review in Psychological Bulletin concluded that no well-designed randomized trial has shown psychotherapy prolongs survival in cancer. However, evidence from 29 randomized trials shows mindfulness reduces stress, anxiety, depression, fear of recurrence, fatigue and sleep problems, though the effects are small. The mind helps people stay on treatment and live better, alongside medicine, not instead of it.

While on anti-angiogenic therapy, which symptoms need the hospital right away?

Go to hospital immediately for sudden severe abdominal pain or a rigid abdomen, repeated vomiting with no gas or stool, a rapidly swelling abdomen, fever of 38 °C or higher, severe headache with blurred vision or confusion, vomiting or passing blood, rapidly worsening breathlessness, one-sided leg swelling, or sudden chest pain. People with cancer spread in the abdomen have a higher risk of bowel obstruction and perforation.

Can recurrent stage 4 ovarian cancer be cured?

At this stage the main goal is usually to control the disease for as long as possible with good quality of life, much like a chronic illness. Many patients alternate between remission and treatment for years. In the SOLO2 trial, people with a BRCA mutation who received olaparib had a median survival of 51.7 months. Some carefully selected patients may have repeat surgery. Individual outlook should be discussed with the treating doctor.

How should I exercise and eat during long-term treatment?

Exercise guidelines for people with cancer recommend about 30 minutes of moderate aerobic activity 3 times a week and resistance training twice a week to reduce fatigue, anxiety and depression, adjusted to energy levels and medical advice. For food, aim for enough protein, eat small frequent meals if ascites makes you feel full, limit salt if blood pressure is high, and ask your doctor before taking any herbs or high-dose supplements.

Scientific mechanism

Summary by Asst. Prof. Dr. Norawit Raatpiboon:
tumors larger than about 1–2 mm need new blood vessels driven by VEGF signaling, which also makes vessels leaky and contributes to ascites. Bevacizumab binds VEGF, pruning abnormal vessels so the tumor loses blood supply and ascites falls. But VEGF also maintains normal vessel walls, the kidneys and wound repair, which explains high blood pressure, proteinuria and bowel perforation.
PARP inhibitors block an enzyme that repairs single-strand DNA breaks. Cancer cells lacking homologous recombination repair because of BRCA mutations accumulate damage and die, a principle called synthetic lethality.
Antibody-drug conjugates bind folate receptor alpha on cancer cells, are taken inside and release a chemotherapy payload that disrupts microtubules within the target cell.
On the mind side, chronic stress raises catecholamines and cortisol, which in the laboratory suppress NK cell activity and stimulate VEGF. In humans, however, the data remain associational, and reducing stress has not been proven to change cancer treatment outcomes.

Related guides